Skip to main content

Table 2 Guselkumab treatment effect on FACIT-Fatigue score at week 24 and week 52

From: Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis

  DISCOVER-1 DISCOVER-2
Guselkumab 100 mg Q4W Guselkumab 100 mg Q8W Placebo to Guselkumab 100 mg Q4W at W24 Guselkumab 100 mg Q4W Guselkumab 100 mg Q8W Placebo to Guselkumab 100 mg Q4W at W24
W 24 W 52 W 24 W 52 W 24 W 52 W 24 W 52 W 24 W 52 W 24 W 52
N 125 124 123 114 114 104 234 229 238 234 237 230
Observed mean change in FACIT-Fatigue score 5.6 6.9 5.9 7.5 2.6 6.6 7.0 7.7 8.0 8.9 3.8 7.5
 (SD) (7.8) (8.4) (10.4) (9.6) (8.3) (9.4) (8.6) (9.1) (9.9) (9.5) (9.0) (9.4)
Cohen’s d effect sizea 0.55 0.68 0.52 0.66 0.26 0.65 0.75 0.84 0.81 0.91 0.41 0.80
  1. FACIT Functional Assessment of Chronic Illness Therapy, Q4W every 4 weeks, Q8W every 8 weeks, SD standard deviation, W week
  2. aThe effect size of changes from baseline in FACIT-Fatigue scores, based on the observed data, was calculated by dividing the change in FACIT-Fatigue score from baseline by the SD of baseline scores [24]